Ginsenoside Rg3 drug loading system as well as preparation method and application thereof
By preparing G-Rg3@BSPs-SA polymer nanomicelles and loading them into colonic capsules, the mannose receptor of BSPs mediated targeting M2-TAMs was solved, and the problem of low bioavailability of ginseng saponin Rg3 was achieved. Effective inhibition of colorectal cancer and regulation of immune microenvironment significantly prolonged the survival time of mice.
Patent Information
- Application Number
- CN202411062039.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-05
AI Technical Summary
Ginseng saponin Rg3 has poor water solubility, weak fat solubility and short half-life, which leads to low bioavailability in the body and is difficult to effectively inhibit the development of colorectal cancer.
G-Rg3@BSPs-SA polymer nanomicelles were prepared by emulsifying solvent volatilization method and loaded into colonic capsules. The mannose receptor of BSPs mediated targeting M2-TAMs to promote colon cancer cells release and function.
It improves the availability of drugs in the colon, achieves a dual targeting effect on colon cancer, inhibits tumor cell growth and regulates the immune microenvironment, significantly prolongs the survival time of mice and reduces the weight of intestinal tumors.
Smart Images

Figure CN119033796A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of ginsenoside Rg3 drug preparation, and in particular relates to a ginsenoside Rg3 drug delivery system and a preparation method and application thereof. Background Art
[0002] Colorectal cancer (CRC) is a common malignant tumor of the digestive tract. It is a malignant tumor that occurs in the colorectal mucosal epithelium and glandular part due to the combined effects of multiple pathogenic factors (such as genes, diet and environment). It has a high incidence of cancer worldwide and seriously endangers life and health. Its early diagnosis rate is low. Most patients are diagnosed in the middle and late stages, and some have already developed metastasis.
[0003] Ginsenoside Rg3 (G-Rg3) is a tetracyclic triterpenoid saponin extracted from ginseng. It is the main component of the new anticancer drug "Shenyi Capsule" and has good anticancer activity. G-Rg3 can not only "strengthen the body" by regulating TME and improving the body's immunity, but also directly act on tumor cells to inhibit proliferation and migration and promote apoptosis to "detoxify", thus achieving multi-target and multi-link treatment of CRC. As a tetracyclic triterpenoid saponin component in ginseng, G-Rg3 has poor water solubility, weak fat solubility, short half-life, and difficulty in self-assembly in the shell-core structure. After oral administration, it enters the gastrointestinal tract and is metabolized by enzymes or intestinal bacteria. It also has a first-pass effect and low blood drug concentration. The bioavailability is only 2.63%, which greatly limits its clinical application.
[0004] The oral colon-specific drug delivery system (OCDDS) can release drugs in the ileocecal region or colon instead of the upper digestive tract, exerting local or systemic therapeutic effects. It is often used in the treatment of colon diseases, such as ulcerative colitis and colon cancer, which is beneficial for drug accumulation in the diseased part, improving bioavailability and patient compliance.
[0005] Bletilla striata polysaccharides (BSPs) are water-soluble polysaccharides extracted from the dried tubers of Bletilla striata (Thunb.) Reichb.f, a traditional Chinese medicine of the orchid family. BSPs are easily soluble in hot water, slightly soluble in cold water, and insoluble in ethanol. The monosaccharide composition is relatively consistent, mostly composed of mannose (Mannose, Man) and glucose (Glucose, Glc) bonded by 1→4 glycosidic bonds, with a ratio of 4:1-2:1 and a molecular weight distribution of 1.0×10 4 ~1.0×10 5Da. BSPs themselves have multiple pharmacological activities such as hemostasis, wound healing, gastrointestinal mucosal protection, anti-inflammatory, anti-oxidation, anti-tumor and immune regulation. As a natural polymer material, BSPs have the characteristics of stable structure, biodegradability and high biosafety. They are often widely used in pharmaceutical raw materials and pharmaceutical excipients, playing the role of "drug-excipient integration". Because BSPs contain a large number of active hydroxyl groups on the main chain, they are easy to structurally modify. Different design strategies are used to modify their structural matrix to obtain carrier materials with different functions.
[0006] BSPs are hydrophilic polymer materials. By introducing hydrophobic groups, such as cholesteryl succinate, amphiphilic nanocarriers can be prepared. In the aqueous phase, they can form a nanomicelle system with a core-shell structure through self-assembly. The hydrophobic core is conducive to encapsulating poorly soluble anti-tumor drugs, improving drug bioavailability, and passively targeting tumor tissues through the enhanced permeability and retention effect (EPR). Summary of the invention
[0007] The purpose of the present invention is to provide a G-Rg3@BSPs-SA colon-soluble capsule and a preparation method thereof. The G-Rg3@BSPs-SA colon-soluble capsule prepared by the present invention can be degraded in a specific pH environment of the colon to release G-Rg3@BSPs-SA polymer micelles. A large number of exposed Man molecules in BSPs bind to Man-R highly expressed on colon cancer cells and M2-TAMs, respectively, promote cell uptake in an active targeted manner, and release drugs in the intracellular lysosomal environment (pH 5.0), respectively exerting their dual effects of "strengthening the body and detoxifying", improving the availability of drugs in the colon, and exerting anti-tumor effects, such as Figure 1 shown.
[0008] Ginsenoside Rg3 is a drug with the effect of "strengthening the body and detoxifying". Due to its weak lipid solubility and difficulty in self-assembly in the shell-core structure, the present invention adopts an emulsified solvent volatilization method to improve the preparation process. The present invention adopts an emulsified solvent volatilization method to prepare G-Rg3@BSPs-SA polymeric micelles, and evaluates their in vitro drug release behavior. It is loaded into a colon-soluble capsule shell to prepare G-Rg3@BSPs-SA OCDDS, and its drug release behavior and preliminary stability are investigated. Through the dual targeting function of tumor cells and M2-TAMs, the multi-link regulatory effect of "inhibiting tumor cell growth and regulating the immune microenvironment" on colon cancer is achieved, thereby effectively inhibiting the occurrence and development of colon cancer.
[0009] In order to achieve the above tasks, the present invention is implemented through the following technical solutions:
[0010] A G-Rg3@BSPs-SA colon-soluble capsule, characterized in that it is composed of the following components: ginsenoside Rg3 raw material, an amphiphilic Bletilla striata polysaccharide polymer carrier, and a colon-soluble capsule shell.
[0011] The amphiphilic Bletilla striata polysaccharide polymer carrier includes the following two compounds:
[0012] (a) Bletilla striata polysaccharides (BSPs), hydrophilic polymer materials.
[0013] (b), stearic acid (SA), hydrophobic group.
[0014] The above-mentioned G-Rg3@BSPs-SA colon-soluble capsules are prepared by extracting BSPs from the Chinese herbal medicine Bletilla striata by water extraction and alcohol precipitation, and then purified by steps such as defatting and decolorization, and savag deproteinization to obtain crude polysaccharide of Bletilla striata, and then purified by DEAE-52 and SephadexG-200 to obtain BSPs. The BSPs-SA polymer is synthesized by using a ratio of n(SA):n(DMAP):n(EDC)=1:1:1.2.
[0015] The above-mentioned G-Rg3@BSPs-SA polymer nanomicelles were prepared by dialysis method. BSPs-SA polymer micelles were obtained by self-assembly to obtain a clear and transparent polymer solution. TEM observation showed that the micelles were spherical and relatively evenly distributed. The particle size was determined by Malvern particle size analyzer to be 145.12±8.54nm, PDI was 0.18±0.012 (PDI<0.3), and ζ potential was -23.3±0.031mv. There was no significant difference in particle size, dispersion index and ζ potential of the nanomicelles within 7 days (p>0.05). The BSPs-SA polymer nanomicelles have good stability and can be used for subsequent drug delivery.
[0016] The G-Rg3@BSPs-SA polymer nano-micelles were prepared by emulsification solvent evaporation method, and were spherical, with a particle size of 185.43±1.34nm, a PDI of 0.21±0.01, a ζ potential of -19.2±0.32mv, a drug loading of 9.54±0.24%, and an encapsulation efficiency of 83.90±2.20%. The 48-hour cumulative release in three different media (pH7.4, pH6.5, and pH5.0) was 65.32±3.22%, 79.56±4.28%, and 85.24±3.42%, respectively. The drug release rate was significantly greater than that of free G-Rg3 drugs, and it was relatively stable in normal colon fluid, accelerated release in the acidic microenvironment of tumors, and was conducive to rapid drug release in the acidic environment of lysosomes after entering the cell.
[0017] The above-mentioned G-Rg3@BSPs-SA colon-soluble capsules do not release drugs in the stomach and small intestine. The cumulative drug release in simulated colon fluid for 48 hours is 63.54±3.12%, which can increase the accumulation of drugs in the colon.
[0018] The above-mentioned G-Rg3@BSPs-SA polymer nanomicelles used Coumarin-6 as a fluorescent probe and observed the cellular uptake effect using a fluorescence microscope. Coumarin-6@BSPs-SA polymer nanomicelles were introduced into cells via mannose receptors, and the uptake rates of CT-26 cells and M2-TAMs were 1.79 times and 1.46 times that of free Coumarin-6, respectively.
[0019] The results of the cytotoxicity assay of the BSPs-SA carrier in the G-Rg3@BSPs-SA polymer nanomicelles using CCK-8 showed that the BSPs-SA carrier had no significant effect on the cell viability of CT-26 cells and M2-TAMs, and had good biosafety.
[0020] The above-mentioned G-Rg3@BSPs-SA colon-soluble capsule refers to a bidirectional colon-targeted drug for oral administration.
[0021] The preparation method of the above-mentioned G-Rg3@BSPs-SA colon-soluble capsules is characterized by being carried out according to the following steps:
[0022] (a) Extraction of BSPs:
[0023] Put the Bletilla striata slices in a 60℃ oven to fully dry, and crush through an 80-mesh sieve. Take 100g of Bletilla striata coarse powder, add 20 times the amount of distilled water, extract in a 90℃ water bath for 5 hours, filter, take the residue, and repeat the extraction 3 times. Filter with nylon gauze, collect and combine the filtrate, concentrate to 1 / 3 of the original volume by rotary evaporation, add 3 times the volume of anhydrous ethanol, and let it stand overnight for full precipitation. Collect the precipitate, vacuum dry, and obtain the Bletilla striata polysaccharide extract.
[0024] Take an appropriate amount of Bletilla striata polysaccharide extract, add 10 times the volume of petroleum ether, reflux extract for 4 hours at 70°C, filter, and collect the residue. Add 10 times the volume of 80% ethanol, reflux extract for 4 hours, and filter to collect the residue.
[0025] Papain (0.5 mg / mL) was added to the polysaccharide aqueous solution after defatting and decolorization, and the pH was adjusted to 7.0 with NaOH solution (1M), and the solution was placed in a 50°C water bath for 2 hours for enzymolysis, placed in a boiling water bath for 10 minutes for enzyme inactivation, and cooled to room temperature. The sevag method was used to remove protein, and the polysaccharide solution was added to a separatory funnel, and 20% sevag reagent (the volume ratio of chloroform to n-butanol was 5:1) was added, and the solution was shaken vigorously for 20 minutes, and then allowed to stand for 4 hours. The denatured protein at the junction of the layers was discarded, and the operation was repeated for no less than 3 times until there was no obvious turbidity at the junction of the layers. The upper layer solution was collected, concentrated to 1 / 3 of the original volume by rotary evaporation, and 3 times the volume of anhydrous ethanol was added, and the solution was allowed to stand overnight for full, and the precipitate was collected and dried to obtain Crude Bletilla striata polysaccharides (C-BSPs).
[0026] (b) Purification of BSPs:
[0027] Weigh 200 mg of C-BSPs and dissolve it in 20 mL of deionized water. Use a rubber-tipped dropper to slowly drip the aqueous solution of Bletilla striata polysaccharide into a DEAE-52 cellulose column (4 cm × 60 cm) for chromatography. Use deionized water and 0.1, 0.2, and 0.5 mol / L NaCl solutions for gradient elution at a flow rate of 1 mL / min, and collect 5 mL in a test tube.
[0028] Weigh 100 mg of crude polysaccharide of Bletilla striata purified by DEAE-52 column chromatography, dissolve in 10 mL of deionized water, and chromatograph through a Sephadex G-200 dextran gel column (2.3 cm × 90 cm). Elute with a 0.02 mol / L NaCl aqueous solution layer at a flow rate of 15 mL / min, and collect 5 mL in a test tube.
[0029] (c) Preparation of BSPs-SA:
[0030] 142.24 mg SA, 61.08 mg 4-dimethylaminopyridine (DMAP) and 93.14 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) were weighed and dissolved in 3 mL DMSO, and activated for 2 h under magnetic stirring at room temperature to obtain an activated reaction solution. 400 mg BSPs were weighed and dissolved in 4 mL DMSO, added dropwise to the activated reaction solution, reacted at 75 ° C for 4 h, and then reacted at room temperature for 24 h. After the reaction, the above reactants were placed in a dialysis bag (3500 Da) and dialyzed for 24 h to remove DMSO, and extracted with an equal volume of ethyl acetate for 3 times to remove unreacted SA, and rotary evaporated at 40 ° C to remove ethyl acetate. The product was freeze-dried to obtain BSPs-SA.
[0031] (d) Preparation of BSPs-SA polymer micelles:
[0032] BSPs-SA polymer micelles were prepared by dialysis. 25.0 mg BSPs-SA was accurately weighed, 5 mL DMSO was added to completely dissolve it, and then all of it was transferred to a dialysis bag (8000 Da). The dialysis bag was placed in 500 mL pure water for dialysis at room temperature, and the water was changed every 8 hours for a total of 48 hours. After passing through a 0.45 μm microporous filter membrane, the volume was transferred to a 25 mL volumetric flask to obtain a blank polymer micelle solution.
[0033] (e) Preparation of G-Rg3@BSPs-SA polymer nanomicelles:
[0034] Weigh 25 mg of BSPs-SA accurately, add 4 mL of DMSO to completely dissolve, and transfer all of it to a dialysis bag (8-14 kDa). Place the dialysis bag in 500 mL of pure water for dialysis at room temperature, change the water every 8 hours, and dialyze for a total of 48 hours. Pass through a 0.45 μm microporous filter membrane, transfer to a 25 mL volumetric flask to obtain a 1 mg / mL blank micelle solution. Weigh 5 mg of G-Rg3 accurately and dissolve it in 2.5 mL of methanol to obtain a 2 mg / mL G-Rg3 solution. Take 1.6 mL of G-Rg3 solution and drip it dropwise into the blank BSPs-SA micelle at 250 rpm, stir at room temperature for 4 hours, evaporate the methanol, pass through a 0.45 um microporous filter membrane, and freeze-dry to obtain the G-Rg3@BSPs-SA polymer micelle freeze-dried powder.
[0035] (f) Preparation of G-Rg3@BSPs-SA colon-soluble capsules:
[0036] Weigh an appropriate amount of G-Rg3@BSPs-SA polymer nano-micelle freeze-dried powder and directly fill it into a colon-soluble capsule for mice (provided by Huangshan Capsule Co., Ltd.). After filling, apply glue at the interface between the capsule cap and the capsule body and dry it. The amount of polymer micelle powder in each capsule is 4 mg, containing about 0.4 mg of G-Rg3.
[0037] The present invention is beneficial in that:
[0038] The invention discloses a ginsenoside Rg3 colon-soluble capsule and a preparation method thereof. The prepared G-Rg3@BSPs-SA colon-soluble capsule is an oral bidirectional colon-targeted preparation. The ginsenoside Rg3@BSPs-SA OCDDS can be mediated by mannose receptors, target M2-TAMs to promote reprogramming to M1 type, reduce TGF-β, increase TNF-α, induce CD8+T cell infiltration, reverse the immunosuppressive environment, and reconstruct the tumor microenvironment to "rectify"; target colon cancer cells to inhibit cell proliferation, migration and invasion, promote cell apoptosis, down-regulate the expression of snail nuclear transcription factor to inhibit epithelial-mesenchymal transition, inhibit tumor growth and "detoxify", and effectively control the occurrence and development of colon cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1 Schematic diagram of the action of the ginsenoside Rg3 dual-targeted oral colon-localized drug delivery system.
[0040] Figure 2 A is the appearance of BSPs-SA polymer micelle solution. Figure 2 B is the transmission electron microscopy image of BSPs-SA polymer micelles.
[0041] Figure 3 A is the change of particle size and PDI of BSPs-SA polymer micelles within 7 days. Figure 3 B is the change of ζ potential of BSPs-SA polymer micelles within 7 days.
[0042] Figure 4 A is the particle size and dispersion index of G-Rg3@BSPs-SA polymer micelles prepared by different methods, Figure 4 B shows the drug loading and encapsulation efficiency of G-Rg3@BSPs-SA polymer micelles prepared by different methods.
[0043] Figure 5 A is the particle size and dispersion index of G-Rg3@BSPs-SA polymer micelles prepared with different G-Rg3 solution concentrations. Figure 5 B shows the drug loading and encapsulation efficiency of G-Rg3@BSPs-SA polymer micelles prepared with different G-Rg3 solution concentrations.
[0044] Figure 6A is the particle size and dispersion index of G-Rg3@BSPs-SA polymer micelles prepared with different G-Rg3 / BSPs-SA mass ratios. Figure 6 B is the drug loading capacity and encapsulation efficiency of G-Rg3@BSPs-SA polymer micelles prepared with different G-Rg3 / BSPs-SA mass ratios.
[0045] Figure 7 A is the transmission electron microscopy image of G-Rg3@BSPs-SA micelles at pH = 7.4. Figure 7 B is the transmission electron microscopy image of G-Rg3@BSPs-SA micelles at pH = 5.0. Figure 7 C is a transmission electron microscopy image of G-Rg3@BSPs-SA micelles at a magnification of ×2 at pH = 5.0.
[0046] Figure 8 A is the particle size of G-Rg3@BSPs-SA polymer nanomicelles at pH = 7.4. Figure 8 B is the particle size of G-Rg3@BSPs-SA polymer nanomicelles at pH = 5.0. Figure 8 C is the zeta potential of G-Rg3@BSPs-SA polymer nanomicelles at pH = 7.4, Figure 8 D is the zeta potential of G-Rg3@BSPs-SA polymer nanomicelles at pH = 5.0.
[0047] Fig. 9 In vitro release curves of G-Rg3 and G-Rg3@BSPs-SA polymer nanomicelles under different pH conditions.
[0048] Fig.10 In vitro release curves of G-Rg3 colon-coated capsules and G-Rg3@BSPs-SA colon-coated capsules.
[0049] Fig.11 Fluorescence microscopy was used to observe the effects of Coumarin-6 and Uptake of Coumarin-6@BSPs-SA (scale bar: 50 μm). Fig.11 A is a representative fluorescence image of CT-26 cells taking up Coumarin-6 and Coumarin-6@BSPs-SA. Fig.11 B is the fluorescence intensity analysis of Coumarin-6 and Coumarin-6@BSPs-SA uptake by CT-26 cells. Fig.11 C is a representative fluorescence image of the uptake of Coumarin-6 and Coumarin-6@BSPs-SA by CT-26 cells after mannose treatment. Fig.11D is the expression of Coumarin-6 and Fluorescence intensity analysis of Coumarin-6@BSPs-SA uptake (scale bar: 50 μm).
[0050] Fig.12 A is a representative fluorescence image of the uptake of Coumarin-6 and Coumarin-6@BSPs-SA by M2-TAMs after pre-treatment with mannoside. Fig.12 B is the fluorescence intensity analysis of Coumarin-6 and Coumarin-6@BSPs-SA uptake by M2-TAMs after pre-treatment with mannoside (scale bar: 50 μm).
[0051] Fig.13 A is the effect of G-Rg3 and G-Rg3@BSPs-SA polymer micelles on the survival rate of CT-26 cells. Fig.13 B shows the effect of G-Rg3 and G-Rg3@BSPs-SA polymer micelles on the survival rate of M2-TAMs cells.
[0052] Fig.14 Statistical analysis of early apoptosis, late apoptosis and total apoptosis rate of CT-26 cells in vitro (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001)
[0053] Fig.15 The scratch experiment was used to investigate the effects of each group of drugs on the wound healing ability of CT-26 cells.
[0054] Fig.16 The Transwell method was used to investigate the effects of drugs on the migration and invasion of CT-26 cells. Fig.16 A is a representative picture of CT-26 migrating cells; Fig.16 B is a representative picture of CT-26 invasion cells; Fig.16 C is the migration rate of CT-26 cells; Fig.16 D is the invasion rate of CT-26 cells (scale: 50 μm, Mean ± SD, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)
[0055] Fig.17 A shows the cytotoxicity of G-Rg3 and G-Rg3@BSPs-SA polymer micelles at different concentrations to CT-26 cells in the Transwell co-culture model. Fig.17B shows the cytotoxicity results of each group of preparations (G-Rg3: 20 μM) on CT-26 cells in the Transwell co-culture model (Mean±SD, n=3, *p<0.05, ***p<0.0005, ****p<0.0001).
[0056] Fig.18 The in vivo distribution of each group of drugs in CT-26 orthotopic colon cancer mice at different time points.
[0057] Fig.19 A is an in vitro fluorescent image of the intestine of a mouse with CT-26 orthotopic colon cancer. Fig.19 B is the in vitro fluorescence intensity analysis of the intestine of mice with CT-26 orthotopic colon cancer. Fig.19 C is the in vitro fluorescence image of the main organs of mice with CT-26 orthotopic colon cancer. Fig.19 D is the in vitro fluorescence intensity analysis of the main organs of mice bearing CT-26 orthotopic colon cancer.
[0058] Fig. 20 A is a schematic diagram of CT-26 in situ colon cancer modeling and drug administration. Fig. 20 B is the tumor bioluminescence in vivo imaging of CT-26 orthotopic colon cancer mice on days 0, 7, and 14 after administration. Fig. 20 C is the curve of tumor bioluminescence intensity change on days 0, 7, and 14 after administration of CT-26 orthotopic colon cancer mice. Fig. 20 D is the tumor inhibition rate of each group of preparations on the 14th day after administration to mice with CT-26 orthotopic colon cancer (mean±SD, n=15).
[0059] Fig.21 A is the survival time of CT-26 carcinoma in situ mice after drug treatment in each group. Fig.21 B is the weight change of CT-26 carcinoma in situ mice after drug treatment in each group. Fig.21 C shows the intestinal tumor morphology and number of CT-26 carcinoma in situ mice after drug treatment in each group. Fig.21 D is the weight of intestinal tumors in CT-26 carcinoma in situ mice after drug treatment in each group.
[0060] Fig. 22 Pathological observation of tumor tissue and major organs (scale: 50 μm).
[0061] Fig.23 The TUNEL method was used to detect the apoptosis of tumor cells in CT-26 carcinoma in situ mice (scale bar: 50μm).
[0062] Fig.24 Immunofluorescence detection of Ki67 expression in tumor tissue of CT-26 carcinoma in situ mice (scale bar: 50 μm).
[0063] Fig.25 Determination of the fluorescence intensity of CD206 and CD86 in the tumor tissues of CT-26 orthotopic colon cancer mice in each group after drug administration (scale bar: 50 μm)
[0064] Fig.26 A is the relative fluorescence intensity of CD206 in the tumor tissue of CT-26 orthotopic colon cancer mice in each group after administration. Fig.26 B is the relative fluorescence intensity of CD86 in the tumor tissues of CT-26 orthotopic colon cancer mice in each group after drug administration.
[0065] Fig. 27 A is a representative fluorescence image of CD8+T cells in the tumor tissue of CT-26 orthotopic colon cancer mice in each group after drug administration. Fig. 27 B is the relative fluorescence intensity analysis of CD8+T cells in the tumor tissues of CT-26 orthotopic colon cancer mice in each group after administration. (Scale bar: 50μm)
[0066] Fig.28 A is the ELISA test of TNF-α levels in the tumor tissue supernatant of CT-26 orthotopic colon cancer mice in each group after administration. Fig.28 B is the level of TGF-β in the supernatant of tumor tissue of CT-26 orthotopic colon cancer mice in each group after administration detected by ELISA.
[0067] Fig.29 A is the immunofluorescence determination of E-cadherin in the tumor tissues of CT-26 orthotopic colon cancer mice in each group after administration. Fig.29 B is the immunofluorescence determination of N-cadherin in the tumor tissues of CT-26 orthotopic colon cancer mice in each group after administration. Fig.29 C is the immunofluorescence assay of Vimentin in the tumor tissues of CT-26 orthotopic colon cancer mice in each group after drug administration. Fig.29 D is the immunofluorescence determination of Snail in the tumor tissue of CT-26 orthotopic colon cancer mice in each group after administration. (Scale bar: 50μm) DETAILED DESCRIPTION
[0068] In the following examples, the ratio of SA, DMAP and EDC when synthesizing BSPs-SA polymers, and the preparation process of BSPs-SA polymer nano-micelles are preferably:
[0069] The BSPs-SA polymer was synthesized using a ratio of n(SA):n(DMAP):n(EDC)=1:1:1.2. The BSPs-SA polymer micelles were prepared by dialysis. The dialysis bag was placed in 500 mL of pure water for dialysis at room temperature, and the water was changed every 8 hours for a total of 48 hours.
[0070] In the following examples, the preparation process of G-Rg3@BSPs-SA polymer nanomicelles is preferably:
[0071] G-Rg3@BSPs-SA polymer micelles were prepared by emulsification solvent evaporation method. The concentration of G-Rg3 was 2 mg / mL, the concentration of BSPs-SA polymer micelles was 1 mg / mL, the mass ratio of G-Rg3 / BSPs-SA was 1:8, the rotation speed was 250 rpm at room temperature, and the stirring time was 4 h.
[0072] Embodiment 1:
[0073] 1) 142.24 mg SA, 61.08 mg 4-dimethylaminopyridine (DMAP) and 93.14 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) were weighed and dissolved in 3 mL DMSO, and activated with magnetic stirring at room temperature for 2 h to obtain an activated reaction solution;
[0074] 2) Weigh 400 mg of BSPs and dissolve it in 4 mL of DMSO, add it dropwise to the activation reaction solution, react at 75°C for 4 hours, and then react at room temperature for 24 hours. After the reaction, put the above reactants into a dialysis bag (3500Da) and dialyze for 24 hours to remove DMSO, and extract with an equal volume of ethyl acetate for 3 times to remove unreacted SA, and remove ethyl acetate by rotary evaporation at 40°C. The product is freeze-dried to obtain BSPs-SA;
[0075] 3) Accurately weigh 25.0 mg of BSPs-SA, add 5 mL of DMSO to completely dissolve it, and then transfer all of it to a dialysis bag (8000 Da). Place the dialysis bag in 500 mL of pure water for dialyzing at room temperature, changing the water every 8 hours for a total of 48 hours. Pass the filter through a 0.45 μm microporous membrane, transfer to a 25 mL volumetric flask to obtain blank BSPs-SA polymer micelles.
[0076] The BSPs-SA polymer micelles in Example 1 were observed by transmission electron microscopy, their particle size and zeta potential were measured, and their stability was investigated. The results showed that the prepared BSPs-SA polymer micelles were clear and transparent polymer solutions with regular spherical shapes, as shown in FIG. Figure 2As shown. The particle size of BSPs-SA polymer micelles was 145.12±8.54nm, PDI was 0.18±0.012, the dispersion was good, and the ζ potential was -23.3±0.031mv. There was no significant difference in the particle size, dispersion index and ζ potential of the carrier micelles within 1 week (p>0.05). The amphiphilic polymer nano-micelles BSPs-SA prepared by dialysis method had good stability, as shown Figure 3 shown.
[0077] Embodiment 2:
[0078] 1) After the BSPs-SA polymer micelles of Example 1 were completely dissolved by adding DMSO, all of them were transferred to a dialysis bag (8-14 kDa), and the dialysis bag was placed in 500 mL of pure water for dialysis at room temperature, and the water was changed every 8 hours for a total of 48 hours. After filtering through a 0.45 μm microporous membrane, the micelles were transferred to a 25 mL volumetric flask to obtain a blank micelle solution;
[0079] 2) Dissolve the prescribed amount of G-Rg3 in methanol, take an appropriate amount and drip it dropwise into the blank BSPs-SA carrier micelles under stirring conditions, stir at an appropriate temperature to evaporate the organic reagent methanol, pass through a 0.45 μm microporous filter membrane, and freeze-dry to obtain G-Rg31@BSPs-SA.
[0080] Embodiment 3:
[0081] 1) The BSPs-SA polymer micelles of Example 1 were dispersed in DMSO, and an appropriate amount of G-Rg32 was weighed and dissolved in DMSO, and the two were mixed overnight;
[0082] 2) Use deionized water to dialyze continuously for 32 hours to remove DMSO, replace the solution with fresh one every 12 hours to remove excess G-Rg3, and then freeze-dry to obtain G-Rg32@BSPs-SA.
[0083] Embodiment 4:
[0084] 1) The BSPs-SA polymer micelles of Example 1 were dissolved in deionized water, and an appropriate amount of G-Rg33 was dissolved in DMSO.
[0085] 2) Use a syringe to add the G-Rg33 solution dropwise into the BSPs-SA aqueous solution, ultrasonicate for 30 minutes, filter through a 0.45 um microporous filter membrane, and collect the precipitate by centrifugation to obtain G-Rg33@BSPs-SA.
[0086] The particle size, PDI, LC and EE of Example 2, Example 3 and Example 4 were measured to screen out the best preparation method. Flocculent precipitation occurred during the preparation of polymer nano-micelles in Example 4, while the polymer micelles prepared in Example 2 and Example 3 were clear and transparent. In contrast, the preparation prepared in Example 2 had a smaller particle size and PDI, a higher drug loading and encapsulation efficiency, as shown in FIG. Figure 4 shown.
[0087] Embodiment 5:
[0088] G-Rg3: 5 mg was dissolved in 2.5 mL methanol, BSPs-SA: 25 mg was dissolved in 4 mL DMSO, and after dialysis for 48 h, the volume was transferred to a 25 mL volumetric flask. Under magnetic stirring, other factors were fixed, and the concentration of G-Rg3 solution was selected to be 1.00 mg / mL, 2.00 mg / mL and 3.00 mg / mL. The G-Rg3 methanol solution was slowly dripped into the BSPs-SA blank carrier micelles, and the stirring time was 2 h, the temperature was 30 ° C, and the rotation speed was 100 rpm. The G-Rg3@BSPs-SA polymer nano-micelles were prepared by the method in Example 2.
[0089] Embodiment 6:
[0090] G-Rg3: 5 mg was dissolved in 2.5 mL methanol, BSPs-SA: 25 mg was dissolved in 4 mL DMSO, and after dialysis for 48 h, the volume was transferred to a 25 mL volumetric flask. Under magnetic stirring, other factors were fixed, and different G-Rg3 / BSPs-SA mass ratios (1:3, 1:5, 1:8, 1:10, 1:12) were selected, and the G-Rg3 methanol solution was slowly dripped into the BSPs-SA blank carrier micelles, with a stirring time of 2 h, a temperature of 30 ° C, and a rotation speed of 100 rpm. The G-Rg3@BSPs-SA polymer nano-micelles were prepared by the method in Example 2.
[0091] Embodiment 7:
[0092] G-Rg3: 5 mg was dissolved in 2.5 mL methanol, BSPs-SA: 25 mg was dissolved in 4 mL DMSO, and after dialysis for 48 h, the volume was transferred to a 25 mL volumetric flask. Under magnetic stirring, the G-Rg3 methanol solution was slowly dripped into the BSPs-SA blank carrier micelles, the stirring time was 2 h, the temperature was 30 ° C, other factors were fixed unchanged, different speeds (100 rpm, 250 rpm, 500 rpm) were selected, and the G-Rg3@BSPs-SA polymer nano-micelles were prepared by the method in Example 2.
[0093] Embodiment 8:
[0094] G-Rg3: 5 mg was dissolved in 2.5 mL methanol, BSPs-SA: 25 mg was dissolved in 4 mL DMSO, and after dialysis for 48 h, the volume was transferred to a 25 mL volumetric flask. Under magnetic stirring, the G-Rg3 methanol solution was slowly dripped into the BSPs-SA blank carrier micelles, the temperature was 30 ° C, the speed was 100 rpm, and other factors were fixed unchanged. Different stirring times (2 h, 4 h, 8 h) were selected, and the G-Rg3@BSPs-SA polymer nano-micelles were prepared by the method in Example 2.
[0095] Embodiment 9:
[0096] G-Rg3: 5 mg was dissolved in 2.5 mL methanol, BSPs-SA: 25 mg was dissolved in 4 mL DMSO, and after dialysis for 48 h, the volume was transferred to a 25 mL volumetric flask. Under magnetic stirring, the G-Rg3 methanol solution was slowly dripped into the BSPs-SA blank carrier micelles, the stirring time was 2 h, the speed was 100 rpm, and other factors were fixed unchanged. Different reaction temperatures (30 ° C, 50 ° C, 80 ° C) were selected, and the G-Rg3@BSPs-SA polymer nano-micelles were prepared by the method in Example 2.
[0097] The changes in particle size, PDI, LC and EE were observed in Example 5, Example 6, Example 7, Example 8 and Example 9. When the concentration of G-Rg3 solution was 2.00 mg / mL, the particle size of polymer nano-micelles was smaller and the encapsulation efficiency was larger. Figure 5 As shown in the figure, the G-Rg3 / BSPs-SA mass ratio is 1:8 as the prescription dosage, and the drug loading is the best. Figure 6 As shown. When the rotation speed is 250rpm, the PDI value of G-Rg3@BSPs-SA polymer micelles is the smallest, and the drug loading and encapsulation efficiency are the largest. As the stirring time increases, the particle size and PDI tend to decrease. Compared with stirring for 8h, there is no difference in particle size when stirring for 4h. From the perspective of saving time, stirring for 4h is used to prepare drug-loaded polymer micelles. The stirring temperature has no obvious effect on the results, so room temperature is selected as the stirring temperature to prepare polymer micelles.
[0098] According to the optimized prescription process, three G-Rg3@BSPs-SA polymer micelles were prepared in parallel, and their particle size, PDI, LC and EE were determined. The particle size, PDI, LC (%) and EE (%) of G-Rg3@BSPs-SA polymer nanomicelles prepared by the optimal process and prescription were 183.68±4.82nm, 0.21±0.02, 9.54%±0.24 and 83.90%±2.20, respectively, and the process was stable.
[0099] Embodiment 10:
[0100] The G-Rg3@BSPs-SA polymer micelles in Example 2 were observed for their appearance, particle size and zeta potential, and in vitro release studies. The results showed that the prepared G-Rg3@BSPs-SA polymer micelles were spherical in shape with regular particle size of about 180nm at pH 7.4, which was about 35nm larger than the blank micelle particle size and had a relatively uniform distribution. As the pH value decreased, at pH 5.0, the polymer micelle particle size increased slightly to about 205nm. Figure 7 As shown. Under pH 7.4, the micelle size is 185.43±1.34nm, PDI is 0.21±0.01, and ζ potential is -19.2±0.32mV; under pH 5.0, the particle size is 205.65±2.03nm, and the distribution shows a double peak, which may be due to the charge repulsion between particles causing the micelles to swell slightly and the ζ potential to increase slightly, as shown in Figure 2. Figure 8 As shown in Figure 2, the release rate of GRg3@BSPs-SA micelles is significantly greater than that of free G-Rg3 drugs, and the cumulative release rates are 65.32±3.22%, 79.56±4.28%, and 85.24±3.42%, respectively. Fig. 9 shown.
[0101] Embodiment 11:
[0102] Weigh an appropriate amount of the polymer nano-micelle lyophilized powder of Example 2 and directly fill it into a colon-soluble capsule for mice (provided by Huangshan Capsule Co., Ltd.). After filling, apply glue at the interface between the capsule cap and the capsule body and dry it to obtain G-Rg3@BSP-SA colon-soluble capsules. The amount of polymer micelle powder in each capsule is 4 mg, and it contains about 0.4 mg of G-Rg3.
[0103] The G-Rg3@BSP-SA colon-soluble capsules in Example 11 were subjected to in vitro release studies and preliminary stability experiments. Results The prepared G-Rg3@BSP-SA colon-soluble capsules began to release drugs under the condition of pH 7.4 release medium. Within 48 hours, the cumulative drug release of G-Rg3 OCDDS was only 28.12±1.91%, while the cumulative release of G-Rg3@BSPs-SA OCDDS within 48 hours was 63.54±3.12%. Fig.10 After the high temperature, low temperature and strong light irradiation stability tests, the morphology of the G-Rg3@BSPs-SA micelle powder did not change significantly, but after 10 days of high humidity treatment, a small amount of powder was slightly sticky.
[0104] Embodiment 12:
[0105] 1) Accurately weigh 25 mg of BSPs-SA, add 4 mL of DMSO to completely dissolve, and transfer all of it to a dialysis bag (8-14 kDa). Place the dialysis bag in 500 mL of pure water for dialyzing at room temperature, changing the water every 8 hours for a total of 48 hours, filter through a 0.45 μm microporous membrane, transfer to a 25 mL volumetric flask to obtain a 1 mg / mL blank micelle solution.
[0106] 2) Precisely weigh the prescribed amount of coumarin-6 solid powder in a dark place, dissolve it with an appropriate amount of methanol, and prepare a mother solution with a final concentration of 2 mg / mL coumarin-6. Pour it dropwise into the blank BSPs-SA micelles at 250 rpm, stir at room temperature for 4 h, evaporate the methanol, filter it through a 0.45 um microporous membrane, and freeze-dry it to obtain Coumarin-6@BSPs-SA.
[0107] The Coumarin-6@BSPs-SA of Example 12 was used to investigate the uptake of polymer micelles by colon cancer CT-26 cells and M2-TAMs. The results showed that the Coumarin-6@BSPs-SA polymer micelles were introduced into cells mediated by the mannose receptors highly expressed on the surface of CT-26 cells, thereby improving the cell uptake efficiency. The preparation had a CT-26 cell targeting function, such as Fig.11 As shown. The mannose unit in the BSPs-SA carrier structure can bind to the mannose receptors highly expressed on the surface of M2-TAMs cells, targeting M2-TAMs, but not specifically targeting M1-TAMs in the tumor site, laying the foundation for the drug-loaded polymer micelles to regulate the depolarization of M2-TAMs to M1-TAMs, relieve the immunosuppressive environment, and exert immunotherapy effects, as shown. Fig.12 shown.
[0108] Embodiment 13:
[0109] Different concentrations of each group of drugs or carriers were incubated with CT-26 cells and M2-TAMs for 24 h, and the CCK-8 method was used to investigate the effects of free G-Rg3, G-Rg3@BSPs-SA polymer micelles and BSPs-SA on the viability of mouse colon cancer CT-26 cells and M2-TAMs cells. The results showed that both G-Rg3 and G-Rg3@BSPs-SA could effectively inhibit the proliferation of CT-26 cells, and G-Rg3@BSPs-SA polymer micelles showed stronger in vitro antitumor effects, such as Fig.13 shown.
[0110] Embodiment 14:
[0111] Annexin V FITC and PI double staining was used to investigate the effects of G-Rg3, G-Rg3@BSPs-SA, BSPs-SA, and G-Rg3+BSPs-SA physical mixture on CT-26 cell apoptosis by flow cytometry. Fig.14 As shown, G-Rg3@BSPs-SA polymer micelles induced the most obvious apoptosis in CT-26 cells compared with other groups, and mainly induced early apoptosis.
[0112] Embodiment 15:
[0113] The anti-metastatic ability of G-Rg3@BSPs-SA polymer micelles on CT-26 colon cancer cells was evaluated by scratch test. When the cells grew to a fused monolayer state, a blank cell-free area was artificially created on the monolayer cells, which was recorded as the cell scratch width at 0h. The scratch healing was observed at 24h and 48h to determine the effect of the drug on the cell migration ability. The results are shown in Fig.15 As shown, G-Rg3@BSPs-SA polymer micelles showed the strongest ability to inhibit the migration of CT-26 colon cancer cells compared with other groups.
[0114] Embodiment 16:
[0115] Transwell experiments were used to further verify the ability of G-Rg3@BSPs-SA to inhibit the migration and invasion of CT-26 cells. Based on the permeability of the cell membrane and the restrictiveness of the basement membrane, cells were planted in the upper chamber of the Transwell, and culture medium containing chemoattractants or stimulatory factors was added to the lower chamber to promote cell migration to the target area. The migration and invasion ability of cells was evaluated by observing and counting the number of CT-26 cells that passed through the micropores at the bottom of the upper chamber and reached the lower chamber and were stained with crystal violet. The results are shown in Figure 2. Fig.16 As shown, G-Rg3@BSPs-SA polymer micelles significantly inhibited the migration and invasion abilities of CT-26 cells compared with other groups.
[0116] Embodiment 17:
[0117] In order to simulate the tumor microenvironment in vitro, a non-contact co-culture model was established using a Transwell culture plate with a pore size of 0.4 μm. M2-TAMs were placed in the upper chamber of the chamber, and CT-26 cells were placed in the lower chamber of the chamber. The various cytokines, growth factors or chemokines in the upper and lower chambers of the model can smoothly pass through the micropores at the bottom of the chamber to exchange with each other, while the two cells remain in a non-contact and independent state. The G-Rg3@BSPs-SA polymer micelles prepared in this study have better ability to induce tumor-associated macrophages to transform from M2 to M1, upregulate the expression of pro-inflammatory cytokines, downregulate the expression of anti-inflammatory cytokines, relieve the immunosuppressive environment, and reconstruct the tumor immune microenvironment, thereby enhancing the anti-tumor effect. Fig.17 shown.
[0118] Embodiment 18:
[0119] 1) Accurately weigh 25 mg of BSPs-SA, add 4 mL of DMSO to completely dissolve, and transfer all of it to a dialysis bag (8-14 kDa). Place the dialysis bag in 500 mL of pure water for dialyzing at room temperature, changing the water every 8 hours for a total of 48 hours, filter through a 0.45 μm microporous membrane, transfer to a 25 mL volumetric flask to obtain a 1 mg / mL blank micelle solution.
[0120] 2) Accurately weigh an appropriate amount of DiR solid powder, dissolve it with an appropriate amount of anhydrous ethanol, prepare a DiR ethanol solution with a final concentration of 2 mg / mL, and store it at 20°C in a dark place. Pour it dropwise into the blank BSPs-SA micelles at 250 rpm, stir it at room temperature for 4 h, evaporate the methanol, filter it through a 0.45 um microporous membrane, and freeze-dry it to obtain DiR@BSPs-SA.
[0121] The DiR@BSPs-SA polymer micelle solution (containing an equal amount of DiR) in Example 18 was encapsulated into the shell of the mouse colonic capsule, and one capsule was administered to each mouse by gavage as the test group. Ten days after the Balb / c mouse colonic carcinoma in situ modeling, the mice with colonic carcinoma in situ were randomly divided into two groups, with 3 mice in each group. Each mouse in the control group was gavaged with 500 μL of free DiR ethanol solution (0.4 mg / mL). At 1, 2, 4, 8, 12 and 24 hours after gavage, the mice were anesthetized with isoflurane and then placed on an IVIS Spectrum small animal in vivo imager to observe the real-time distribution of fluorescence in the mice. Fig.18 As shown in the figure, DiR@BSPs-SA colon-soluble capsules showed weak fluorescence within 4 hours after intragastric administration, and no drug was released in the stomach and small intestine. At the end of the experiment, the animals were euthanized, the intestines and major organs (heart, liver, spleen, lungs, and kidneys) were dissected, and the tissues and organs were imaged again using the small animal in vivo imaging system to observe the distribution of the drug in vitro for 24 hours. Fig.19 As shown, the DiR@BSPs-SA colon-dissolved capsule group had the strongest fluorescence intensity at the tumor site compared with the other groups, and fluorescence was only observed in the liver.
[0122] Embodiment 19:
[0123] 1) Balb / c male mice weighing 18g-20g were taken and fed at room temperature for one week, fasted for 24h, weighed, and given 20% urethane for intraperitoneal anesthesia at 0.006mL / g. The abdomen was prepared, wiped and disinfected with iodine cotton balls, cut open along the midline of the mouse abdomen with surgical scissors, and the cecum was removed from the abdomen with alcohol-sterilized forceps. A 30G needle was used to inject 50uL of CT-26Luc cell suspension (containing 10μg / μL matrix gel) at a concentration of about 1x106 cells / mL into the cecum wall with a microinjector, and then the cecum was returned to the abdominal cavity, and the peritoneum and skin were closed with suture needles to establish a CT-26 colon carcinoma in situ model;
[0124] 2) Ten days after the modeling of colon carcinoma in situ in Balb / c mice, the mice with colon carcinoma in situ were randomly divided into 6 groups, each with 15 mice, including PBS group, Shenyi capsule content group (referred to as Shenyi capsule group), G-Rg3 colon-soluble capsule group (referred to as free G-Rg3 group), BSPs-SA colon-soluble capsule group (referred to as BSPs-SA group), G-Rg3@BSPs-SA colon-soluble capsule group (referred to as G-Rg3@BSPs-SA group), and G-Rg3+BSPs-SA physical mixture colon-soluble capsule group (referred to as G-Rg3+BSPs-SA group). Oral administration was performed by gavage, once a day, with a single dose of G-Rg3 20 mg / kg, for 14 consecutive days;
[0125] 3) Pharmacodynamics study was conducted using the CT-26 colon carcinoma in situ model of Balb / c mice. When the tumor bioluminescence intensity reached 109p / sec / cm2 / sr, drug administration was started 10 days after modeling. The intensity of bioluminescence in mouse tumors is proportional to the number of tumor cells. The changes in the intensity of bioluminescence in each group of tumors can be used to monitor tumor growth. The small animal in vivo imaging system was used to observe the changes in the fluorescence intensity of each group of tumors on days 0, 7, and 14. The results are shown in Fig. 20 The fluorescence intensity of the G-Rg3@BSPs-SA colon-dissolving capsule group increased the slowest within 14 days, and compared with the positive control drug Can-1 capsule, it significantly improved the tumor inhibition rate of mice with orthotopic colon cancer.
[0126] 4) From the 0th day of administration, the survival of Balb / c mice with colon carcinoma in situ was observed and recorded every day, and the death date and survival time were recorded in time. The observation was continued for 60 days, and the survival curve was analyzed and drawn using Graphpad prism 10.0 software. The weight of mice with colon carcinoma in situ was weighed every 3 days after administration, and the weight changes of mice with colon carcinoma in situ were recorded. The results are shown in Fig.21G-Rg3@BSPs-SA colon-dissolving capsules significantly prolonged the survival time of mice with CT-26 carcinoma in situ and reduced the weight of intestinal tumors in mice with CT-26 carcinoma in situ. In addition, the size and number of intestinal tumors in mice with colon cancer in the G-Rg3@BSPs-SA colon-dissolving capsule group were the smallest.
[0127] 5) After the administration, the mice in each group were dissected, and the tumor tissues in the intestine and the main organs (heart, liver, spleen, lung, and kidney) were taken and fixed with 4% paraformaldehyde for 24 hours. Then the tissues to be tested were taken out, flattened with a scalpel, paraffin sections were prepared and HE stained, and placed under an inverted fluorescence microscope for observation and image collection. The results are shown in Fig. 22 In the G-Rg3@BSPs-SA colon-soluble capsule group, a large number of tumor cells showed apoptosis, the cells were loosely arranged, and other major organs were not significantly affected.
[0128] 6) The TUNEL method was used to detect the apoptosis of tumor cells after treatment with each group of drugs. When cells undergo apoptosis, their nuclear chromatin will break into fragments, and these fragments will be recognized by the luciferase-labeled DNA terminal ligase (Terminal Deoxynucleotidyl Transferase, TdT) and bind to DNA to form terminal labeled DNA. The apoptosis of cells was determined by fluorescence microscopy. The results are shown in Fig.23 The BSPs-SA colon-soluble capsule group had a weaker pro-apoptotic effect, the number of apoptotic cells in the Can-1 capsule and G-Rg3 colon-soluble capsule group increased significantly, and the fluorescence intensity of the G-Rg3@BSPs-SA colon-soluble capsule group was significantly enhanced. G-Rg3 and BSPs-SA showed an excellent synergistic effect.
[0129] 7) Immunofluorescence was used to detect the cell proliferation in CT-26 colon cancer tissues after treatment with each group of drugs. Specific antibodies were used to bind to Ki67 protein to form a complex, which was then combined with a fluorescent dye. The fluorescence intensity and distribution were observed under a fluorescence microscope to examine the effect on cell proliferation. The results are shown in Fig.24 Compared with the PBS control group, the red fluorescence intensity of the G-Rg3@BSPs-SA colon-soluble capsule group was significantly reduced, and the preparation can effectively inhibit the proliferation of CT-26 tumor cells in vivo.
[0130] 8) To verify whether the preparation can effectively reverse M2-TAMs to M1-TAMs, immunofluorescence was used to detect the expression of CD206 (M2-TAMs marker protein) and CD86 (M1-TAMs marker protein) in mouse orthotopic colon tumor tissues. The results are shown in Fig.25 , Fig.26There was no significant difference in the repolarization of M2-TAMs induced by BSPs-SA colon-dissolved capsules compared with the control group (p>0.05), but the combination with G-Rg3 showed a synergistic effect (p<0.001). Compared with the control group, the number of CD206+ macrophages in the tumor tissue of G-Rg3@BSPs-SA colon-dissolved capsules decreased significantly, and the number of CD86+ macrophages increased significantly, with significant differences (p<0.001).
[0131] 9) To further verify the regulation of the in vivo immunosuppressive environment by M2 tumor-associated macrophages after repolarization, this study used immunofluorescence to detect the expression of CD8+T cells in tumor tissues. The results are shown in Fig. 27 Compared with the PBS control group, the fluorescence intensity of the BSPs-SA colon-dissolved capsule group decreased, and the number of CD8+T cells in the other groups increased significantly (p<0.001). The fluorescence intensity of the G-Rg3@BSPs-SA colon-dissolved capsule group increased most significantly, about 9.29 times that of the PBS group (p<0.001).
[0132] 10) 14 days after administration, the levels of TNF-α and TGF-β in the supernatant of the tumor tissues of CT-26 orthotopic colon cancer mice were quantitatively determined using ELISA kits. The results are shown in Fig.28 Compared with the other groups, the G-Rg3@BSPs-SA colon-soluble capsule group had the most significant effect, with the TNF-α concentration increased by 134.83% and the TGF-β concentration decreased by 63.61%.
[0133] 11) To further study the effect of the preparation on the EMT process in vivo, immunofluorescence was used to determine the expression of E-cadherin, N-cadherin, vimentin, and snail protein in the tumor tissues of each group after administration. The results are shown in Fig.29 Compared with the PBS control group, the fluorescence intensity of E-cadherin in each group was upregulated to varying degrees, and the fluorescence intensity of N-cadherin, Vimentin and snail was decreased to varying degrees, indicating that each group can inhibit the occurrence of EMT in colon cancer and thus slow down tumor metastasis. Among them, the G-Rg3@BSPs-SA colon-dissolved capsule group had the most significant effect in inhibiting EMT, and the carrier BSPs-SA showed a synergistic effect with G-Rg3.
Claims
1. A ginsenoside Rg3 (G-Rg3) drug delivery system, characterized in that: The invention is composed of the following components: G-Rg3 and an amphiphilic Bletilla striata polysaccharide polymer carrier.
2. The ginsenoside Rg3 drug delivery system according to claim 1, characterized in that: The amphiphilic bletilla striata polysaccharide polymer carrier comprises bletilla striata polysaccharide (BSPs) and stearic acid (SA), and the mass ratio is 1:0.1-2.
5.
3. The ginsenoside Rg3 drug delivery system according to claim 2, characterized in that: The BSPs are composed of mannose and glucose in a molar ratio of 3.1-4.5:
1.
4. The ginsenoside Rg3 drug delivery system according to any one of claims 1 to 3, characterized in that: The proportion of G-Rg3 in the drug-carrying system is 8.5%-12.0%.
5. A method for preparing the ginsenoside Rg3 drug delivery system according to any one of claims 1 to 4, characterized in that: The following steps are involved: S1: SA and BSPs are dissolved in DMSO for reaction. After the reaction, DMSO and unreacted SA are removed and the product is freeze-dried to obtain BSPs-SA. S2: Take BSPs-SA and add DMSO to dissolve it, transfer it to a 8000Da dialysis bag, place the dialysis bag in pure water for dialysis at room temperature, and fix the volume to obtain blank BSPs-SA polymer nanomicelles; S3: Take the blank BSPs-SA polymer nanomicelle solution, add DMSO to dissolve, transfer to a 8-14kDa dialysis bag, place the dialysis bag in pure water for dialyzing at room temperature, and fix the volume to obtain blank BSPs-SA polymer nanomicelles; take G-Rg3 and dissolve it in methanol, take the G-Rg3 solution, drip it drop by drop into the blank BSPs-SA polymer micelles, remove the methanol, and freeze-dry to obtain G-Rg3@BSPs-SA polymer nanomicelles freeze-dried powder.
6. The method for preparing the ginsenoside Rg3 drug delivery system according to claim 5, characterized in that: The activation reaction conditions in S1 are to react at 75° C. for 4 h and then at room temperature for 24 h.
7. The method for preparing the colon-targeted drug delivery system of ginsenoside Rg3 according to claim 5, characterized in that: The mass ratio of G-Rg3 and BSPs-SA described in S3 is 1:7-11.
8. A pharmaceutical preparation, characterized in that A ginsenoside Rg3 drug delivery system comprising the ginsenoside Rg3 drug delivery system according to any one of claims 1 to 4.
9. Use of the drug delivery system according to any one of claims 1 to 4 or the drug preparation according to claim 8 in the preparation of drugs for treating colon cancer.
10. The pharmaceutical preparation according to claim 8, characterized in that The pharmaceutical preparations are colon-soluble capsules, colon-soluble tablets and colon-soluble granules.
Citation Information
Patent Citations
Method for synthesizing multifunctional active targeted hyaluronic acid-polylactic acid carrier and preparing anti-tumor medicinal micelle of multifunctional active targeted hyaluronic acid-polylactic acid carrier
CN104056275A
Application of gastrodia tuber polysaccharide in preparation of functional food with effect of helping inhibit colon cancer
CN104116023A
PH-sensitive targeted LPNs (lipid poly-L-histidine hybrid nanoparticles) for encapsulating anti-tumor drugs
CN107551277A
Ginsenoside Rg3-loaded rhizoma bletillae polysaccharide microneedle as well as preparation method and application thereof
CN116763716A
Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
US20070298012A1
